Impact of a VI-polysaccharide conjugate vaccine in preventing Typhoid Fever in an endemic setting, Lalitpur, Nepal by Shakya, M

“…</p> <p>In this phase III participant-observer-blind randomized controlled trial, children aged 9 months to under-16 years old, were individually randomized (1:1) to either receive the TCV (Typbar-TCV, Bharat Biotech) or a capsular group A meningococcal conjugate vaccine (MenA) as control, and were followed-up for two years.…”

Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial by Shakya, M, Voysey, M, Theiss-Nyland, K, Colin-Jones, R, Pant, D, Adhikari, A, Tonks, S, Mujadidi, YF, O'Reilly, P, Mazur, O, Kelly, S, Liu, X, Maharjan, A, Dahal, A, Haque, N, Pradhan, A, Shrestha, S, Joshi, M, Smith, N, Hill, J, Clarke, J, Stockdale, L, Jones, E, Lubinda, T, Bajracharya, B, Dongol, S, Karkey, A, Baker, S, Dougan, G, Pitzer, VE, Neuzil, KM, Shrestha, S, Basnyat, B, Pollard, AJ

“…<br><strong> Methods<br></strong> We did a participant-masked and observer-masked individually randomised trial in Lalitpur, Nepal, in which 20 019 children aged 9 months to younger than 16 years were randomly assigned in a 1:1 ratio to receive a single dose of TCV (Typbar TCV, Bharat Biotech International, India) or capsular group A meningococcal conjugate vaccine (MenA). …”